HPA
KERX

Hilltop Park Associates’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Hilltop Park Associates’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-50,000
Closed -$852K – 73
2014
Q1 		$852K Sell
50,000
-50,000
-50% -$754K 0.98% 31
2013
Q4 		$1.29M Sell
100,000
-150,000
-60% -$1.79M 0.97% 34
2013
Q3 		$2.6M Buy
250,000
+200,000
+400% +$1.78M 2.05% 18
2013
Q2 		$374K Buy
+50,000
New +$391K 0.46% 26

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return

Hilltop Park Associates's KERX Position: Q2 2014 in Review

Hilltop Park Associates sold out of Keryx Biopharmaceuticals Inc (KERX) in Q2 2014, closing a stake of 50,000 shares — an estimated $852K sold.

Hilltop Park Associates first reported a position in KERX in Q2 2013 and held it in 4 quarters. The position peaked at $2.6M in Q3 2013. 135 funds tracked by Wall St. Rank hold KERX as of Q2 2014.

  • Hilltop Park Associates reported no remaining Keryx Biopharmaceuticals Inc position as of Q2 2014 after selling out during the quarter.
  • Hilltop Park Associates sold 50,000 Keryx Biopharmaceuticals Inc shares in Q2 2014, an estimated $852K.
  • Hilltop Park Associates first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 4 quarters.
  • Hilltop Park Associates's Keryx Biopharmaceuticals Inc position peaked at $2.6M in Q3 2013.
  • 135 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q2 2014.

Based on Hilltop Park Associates's 13F filing for Q2 2014, filed 14 Aug 2014.